Ultra Processed Foods Consumption and Impact in Rheumatic Diseases.
NCT ID: NCT06776965
Last Updated: 2025-04-11
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
240 participants
OBSERVATIONAL
2025-03-31
2026-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Our primary aim will be to study the pattern of UPF consumption in patients with rheumatic diseases. Our secondary objectives will be to study the activity of diseases according to UPF consumption.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Survey About Diet in Chronic Inflammatory Rheumatic Diseases
NCT05283096
Spondyloarthritis and Nutrition
NCT05289011
Rheumatism and Dietetic: RHUMADIET Study (Food Practices and Beliefs)
NCT03770884
Ecological Momentary Assessment and Physical Activity in Patients With Inflammatory Rheumatic Diseases
NCT07167784
Postprandial Inflammation in Rheumatoid Arthritis
NCT04247009
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Rheumatoid Arthritis
Patients in the first group will correspond to those with rheumatoid arthritis according to ACR criteria of RA
Dietary Questionnaire
Self administered dietary questionnaire at baseline, 6 and 12 months.
Evaluation of disease activity (DAS-28, ASDAS, EVA, number of swollen joints, number of painful joint, nocturnal pain, morning stiffness)
Self administered questionnaire of disease activity at baseline, 6 and 12 months.
Spondyloarthritis
Patients in the second group will correspond to those with spondyloarthritis according ASDAS criteria
Dietary Questionnaire
Self administered dietary questionnaire at baseline, 6 and 12 months.
Evaluation of disease activity (DAS-28, ASDAS, EVA, number of swollen joints, number of painful joint, nocturnal pain, morning stiffness)
Self administered questionnaire of disease activity at baseline, 6 and 12 months.
Osteoarthritis
Patients in the third group will correspond to those with spondyloarthritis according ACR criteria
Dietary Questionnaire
Self administered dietary questionnaire at baseline, 6 and 12 months.
Evaluation of disease activity (DAS-28, ASDAS, EVA, number of swollen joints, number of painful joint, nocturnal pain, morning stiffness)
Self administered questionnaire of disease activity at baseline, 6 and 12 months.
Controls
Patients without rheumatic disease
Dietary Questionnaire
Self administered dietary questionnaire at baseline, 6 and 12 months.
Evaluation of disease activity (DAS-28, ASDAS, EVA, number of swollen joints, number of painful joint, nocturnal pain, morning stiffness)
Self administered questionnaire of disease activity at baseline, 6 and 12 months.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Dietary Questionnaire
Self administered dietary questionnaire at baseline, 6 and 12 months.
Evaluation of disease activity (DAS-28, ASDAS, EVA, number of swollen joints, number of painful joint, nocturnal pain, morning stiffness)
Self administered questionnaire of disease activity at baseline, 6 and 12 months.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* chronic rheumatic disease (Rheumatoid arthritis, spondyloarthritis, osteoarthritis)
* ability to perform questionnaires
Exclusion Criteria
* Refusal to participate in the study
* Suffering from 2 rheumatic disease simultaneously
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hospices Civils de Lyon
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Maxime AUROUX, MD
Role: PRINCIPAL_INVESTIGATOR
Hôpital Edouard Herriot
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Edouard Herriot Hospital
Lyon, , France
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2024-A02327-40
Identifier Type: OTHER
Identifier Source: secondary_id
69HCL24_0947
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.